Doença de Crohn: aspectos do tratamento na atualidade

  • Gabriel Fernandes de Sousa Faculdade de Ciências Médicas da Paraíba
  • Keli Camila Vidal Grochoski Faculdade de Ciências Médicas da Paraíba
  • Rayanir de Freitas Marinho Faculdade de Ciências Médicas da Paraíba
  • Matheus Fragoso Vieira Faculdade de Ciências Médicas da Paraíba
  • Rafael Gonzaga Nahoum Faculdade de Ciências Médicas da Paraíba
Palavras-chave: Doença de Crohn, Tratamento, Gastroenterologia

Resumo

Objetivo: Desvelar a produção científica mais recente a respeito da terapêutica utilizada no tratamento da doença de Crohn (DC). Métodos: Trata-se de uma revisão integrativa da literatura em que se realizou a busca das publicações na Biblioteca Virtual em Saúde (BVS). Foi utilizada a base de dados MEDLINE, através de estudos disponíveis para visualização em revistas de gastroenterologia publicadas entre 2012 e 2016, totalizando 33 artigos. Resultados: Dentre os artigos analisados, 81,8% abordaram a terapia farmacológica, que consiste principalmente em esteroides e imunossupressores e, nos pacientes não responsivos, compostos biológicos como anti-TNF alfa. O adalimumabe apresentou mais efeitos adversos do que o infliximabe. As tiopurinas têm sido associadas à acometimentos hepáticos. A nutrição parenteral total mostrou-se importante, sendo recomendada para pacientes com DC moderada a grave e a nutrição enteral exclusiva para tratamento de primeira linha em crianças com DC. Mostrou-se uma necessidade decrescente de cirurgia após o uso de imunomoduladores. O transplante de microbiota fecal foi relatado como uma terapia alternativa em casos de DC refratária complicada. Conclusões: Observou-se a prevalência de estudos acerca da terapia farmacológica e a necessidade da realização de novos estudos sobre as opções terapêuticas da DC, principalmente no que diz respeito à terapia não farmacológica.

Referências

Casanova MJ, Chaparro M, Valenzuela C, Cisneros C, Gisbert JP. Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease. World J Gastroenterol. 2015; 21(7):2260-2.

Beser OF, Conde CD, Serwas NK, Cokugras FC, Kutlu T, Boztug K, et al. Clinical features of interleukin 10 receptor gene mutations in children with very early-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2015; 60(3):332-8.

Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, et al. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis. 2015; 21(2):323-30.

Gupta V, Rodrigues R, Nguyen D, Sauk J, Khalili H, Yajnik V, et al. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis. Aliment Pharmacol Ther. 2016; 43(1):52-60.

Biancheri P, Brezski RJ, Di Sabatino A, Greenplate AR, Soring KL, Corazza GR, et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology. 2015;149(6):1564-1574.e3.

Hansen LF, Jakobsen C, Paerregaard A, Qvist N, Wewer V. Surgery and postoperative recurrence in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2015; 60(3):347-51.

Benefield LE. Implementing evidence-based practice in home care. Home Healthc Nurse. 2003; 21(12):804-11.

Polit DF, Beck CT. Using research in evidence-based nursing practice. In: Polit DF, Beck CT, editors. Essentials of nursing research. Methods, appraisal and utilization. Philadelphia (USA): Lippincott Williams & Wilkins; 2006. p.457-94.

Souza MT; Silva MD; Carvalho R. Revisão integrativa: o que é e como fazer. Einstein. 2010; 8(1 Pt 1):102-6.

Desales AL; Mendez-Navarro J; Méndez-Tovar LJ; Ortiz-Olvera NX; Cullen G; Ocampo J; Lemus W; et al. Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab. J Crohns Colitis. 2012; 6(4):483-7.

Riis A; Martinsen TC; Waldum HL; Fossmark R. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scand J Gastroenterol. 2012; 47(6):649-57.

Casanova MJ; Chaparro M; Martínez S; Vicuña I; Gisbert JP. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease. J Crohns Colitis. 2012; 6(10):1034-7.

Bonnin P; Coelho J; Pocard M; Levy BI; Marteau P. Anti-TNFα therapy early improves hemodynamics in local intestinal and extraintestinal circulations in active Crohn's disease. J Crohns Colitis. 2013; 7(6):451-9.

Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients. World J Gastroenterol. 2014; 20(22):7019–7026.

Kump PK; Högenauer C; Wenzl HH; Petritsch W. A case of opportunistic skin infection with Mycobacterium marinum during adalimumab treatment in a patient with Crohn's disease. J Crohns Colitis. 2013; 7(1):e15-8.

Tissot C; Couraud S; Meng L; Girard P; Avrillon V; Gérinière L; Perrot E; Souquet PJ. Life-threatening disseminated tuberculosis as a complication of treatment by infliximab for Crohn's disease: report of two cases, including cerebral tuberculomas and miliary tuberculosis. J Crohns Colitis. 2012; 6(9):946-9.

Sebastian S; Ashton K; Houston Y; Diggory TM; Dore P. Anti-TNF therapy induced immune neutropenia in Crohns disease- report of 2 cases and review of literature. J Crohns Colitis. 2012; 6(6):713-6.

Nunes T; Etchevers MJ; Domènech E; García-Sánchez V; Ber Y; Peñalva M; et al. Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther. 2013; 38(7):752-60.

Osterman MT; Haynes K; Delzell E; Zhang J; Bewtra M; Brensinger C; et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol. 2014; 12(5):811-817.e3.

Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; et al. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. Aliment Pharmacol Ther. 2014; 40(9):1044-55.

Bultman E; de Haar C; van Liere-Baron A; Verhoog H; West RL; Kuipers EJ; et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther. 2012; 35(3):335-41.

Chaparro M; Andreu M; Acosta MB; García-Planella E; Ricart E; Domènech E; et al. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol. 2012; 18(37):5219-24.

DeBoer MD; Barnes BH; Stygles NA; Sutphen JL; Borowitz SM. Changes in inflammation and quality of life after a single dose of infliximab during on-going treatment: Differences between patients with and without IBD symptoms at time of administration. J Pediatr Gastroenterol Nutr. 2012; 54(4): 486–490.

Levesque BG; Greenberg GR; Zou G; Sandborn WJ; Singh S; Hauenstein S; et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther. 2014; 39(10):1126-35.

Rosenfeld G; Qian H; Bressler B. The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis. J Crohns Colitis. 2013; 7(11):868-77.

Marques I; Lagos A; Reis J; Pinto A; Neves B. Reversible Henoch-Schönlein purpura complicating adalimumab therapy. J Crohns Colitis. 2012; 6(7):796-9.

Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents. Clin Gastroenterol Hepatol. 2013; 11(7):826-31.

Nuti F, Civitelli F, Bloise S, Oliva S, Aloi M, Latorre G, et al. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort. J Crohns Colitis. 2016; 10(1):5-12.

Sorrentino D; Avellini C; Geraci M; Vadalà S. Pre-clinical Crohn's disease: diagnosis, treatment and six year follow-up. J Crohns Colitis. 2014; 8(7):702-7.

Kwak MS; Kim DH; Park SJ; Kim TI; Hong SP; Kim WH; et al. Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease. BMC Gastroenterol. 2014; 14:85.

Suares NC; Hamlin PJ; Greer DP; Warren L; Clark T; Ford AC. Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. Aliment Pharmacol Ther. 2012; 35(2):284-91.

Tuyama AC; Krakauer M; Alzaabi M; Fiel MI; Legnani P; Schiano TD. Mercaptopurine-induced hepatoportal sclerosis in a patient with Crohn's disease. J Crohns Colitis. 2013; 7(7):590-3.

Connors W; Griffiths C; Patel J; Belletrutti PJ. Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. BMC Gastroenterol. 2014; 14:127.

Gallego-Gutiérrez S, Navas-López VM, Kolorz M, Bartosova L, Lukac K, Luque-Pérez S, et al. Successful Mercaptopurine Usage despite Azathioprine-Induced Pancreatitis in Paediatric Crohn's Disease. J Crohns Colitis. 2015; 9(8):676-9.

Pinto MA; Lopes MS; Bastos ST; Reigada CL; Dantas RF; Neto JC; et al. Does active Crohn's disease have decreased intestinal antioxidant capacity?. J Crohns Colitis. 2013; 7(9):e358-66.

Duncan H; Buchanan E; Cardigan T; Garrick V; Curtis L; McGrogan P; et al. A retrospective study showing maintenance treatment options for paediatric CD in the first year following diagnosis after induction of remission with EEN: supplemental enteral nutrition is better than nothing! BMC Gastroenterol. 2014; 14:50.

Shiga H; Kajiura T; Shinozaki J; Takagi S; Kinouchi Y; Takahashi S; et al. Changes of faecal microbiota in patients with Crohn’s disease treated with an elemental diet and total parenteral nutrition. Dig Liver Dis. 2012; 44:736–742.

Tjellström B; Högberg L; Stenhammar L; Magnusson KE; Midtvedt T; Norin E; Sundqvist T. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease. Scand J Gastroenterol. 2012; 47(12):1454-9.

Zhang FM; Wang HG; Wang M; Cui BT; Fan ZN; Ji GZ. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn’s disease. World J Gastroenterol. 2013; 19(41):7213–7216.

Publicado
2019-11-27
Seção
ARTIGOS DE REVISÃO